← Leaderboards
Zihai Li
Ohio State University
$25,199,729
Attributed
$29,022,386
Total exposure
20
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,187,697 · 22
By mechanism
R01$23,526,478 · 10
P01$10,432,545 · 4
RC1$1,000,000 · 1
K08$678,050 · 1
P30$503,579 · 2
M01$47,045 · 4
Top collaborators
- Nicholas C Denko12 shared
- Terence Marques Williams7 shared
- Raphael E. Pollock2 shared
- Robert Alan Baiocchi1 shared
- Elaine R Mardis1 shared
- Raju R. Raval1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Raphael E. Pollock$16,802,076
- Robert Alan Baiocchi$3,789,234
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsImmuneMolecular ChaperonesEndoplasmic ReticulumResponseCellsProteinsCancer TherapyMolecularInflammationPlayT-LymphocyteBiologyPathway InteractionsKnockout MiceIn VivoHeat Shock ProteinsImmunityComplexBiochemicalLaboratoriesImmunotherapyCell SurfaceLead
Grant awards (96)
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$640,703
R01 · FY2025 · CA
Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer$632,185
R01 · FY2025 · CA · contact PI
Overcoming hypoxic resistance to anti-cancer therapy$582,714
R01 · FY2025 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy$548,899
R01 · FY2025 · CA · contact PI
Sexual Dimorphism in T Cell Exhaustion and Bladder Cancer$514,697
P01 · FY2025 · CA · contact PI
Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer$641,336
R01 · FY2024 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$608,669
R01 · FY2024 · CA
Overcoming hypoxic resistance to anti-cancer therapy$553,580
R01 · FY2024 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy$521,454
R01 · FY2024 · CA · contact PI
Sexual Dimorphism in T Cell Exhaustion and Bladder Cancer$488,963
P01 · FY2024 · CA · contact PI
Targeting the Tumor Microenvironment in Patients with AIDS-Associated EBV+ Diffuse Large B Cell Lymphoma$249,809
P30 · FY2024 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy$68,499
R01 · FY2024 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$627,890
R01 · FY2023 · CA
Overcoming hypoxic resistance to anti-cancer therapy$571,062
R01 · FY2023 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy$537,921
R01 · FY2023 · CA · contact PI
Sexual Dimorphism in T Cell Exhaustion and Bladder Cancer$531,447
P01 · FY2023 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$212,016
R01 · FY2023 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy Supplement$72,104
R01 · FY2023 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$632,109
R01 · FY2022 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy$594,336
R01 · FY2022 · CA · contact PI
Overcoming hypoxic resistance to anti-cancer therapy$571,062
R01 · FY2022 · CA
Diversity Supplement R01CA262388: Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$216,344
R01 · FY2022 · CA
Admin. Suppl. for NCI CCSG/Moonshot Grant to Develop Immune Radiation Response Index (iRRI) for Immune Cells from Normal and Tumor Microenvironments$167,344
P30 · FY2022 · CA
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$650,406
R01 · FY2021 · CA
Overcoming hypoxic resistance to anti-cancer therapy$582,714
R01 · FY2021 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy$569,160
R01 · FY2021 · CA · contact PI
Molecular chaperones and immune tolerance$387,495
R01 · FY2021 · AI · contact PI
Integration of inflammation and cancer by molecular chaperone$176,837
R01 · FY2021 · CA · contact PI
Molecular chaperones and immune tolerance$387,495
R01 · FY2020 · AI · contact PI
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease$351,000
R01 · FY2020 · DK · contact PI
Integration of inflammation and cancer by molecular chaperone$161,151
R01 · FY2020 · CA · contact PI
Cancer Immunology$43,932
P30 · FY2020 · CA · contact PI
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy$1,354,901
P01 · FY2019 · CA · contact PI
Molecular chaperones and immune tolerance$373,750
R01 · FY2019 · AI · contact PI
Core 1: Administration and Biostatistics Core$358,122
P01 · FY2019 · CA · contact PI
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease$336,375
R01 · FY2019 · DK · contact PI
Thrombocytes in Cancer Immunity$225,092
R01 · FY2019 · CA · contact PI
Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance$184,911
P01 · FY2019 · CA · contact PI
Integration of inflammation and cancer by molecular chaperone$168,464
R01 · FY2019 · CA · contact PI
Thrombocytes in Cancer Immunity$150,527
R01 · FY2019 · CA · contact PI
Cancer Immunology$42,494
P30 · FY2019 · CA · contact PI
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy$1,335,301
P01 · FY2018 · CA · contact PI
Thrombocytes in Cancer Immunity$387,236
R01 · FY2018 · CA · contact PI
Molecular chaperones and immune tolerance$373,750
R01 · FY2018 · AI · contact PI
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease$336,375
R01 · FY2018 · DK · contact PI
Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance$222,331
P01 · FY2018 · CA · contact PI
Integration of inflammation and cancer by molecular chaperone$175,721
R01 · FY2018 · CA · contact PI
Core 1: Administration and Biostatistics Core$168,948
P01 · FY2018 · CA · contact PI
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy$1,335,301
P01 · FY2017 · CA · contact PI
Thrombocytes in Cancer Immunity$387,236
R01 · FY2017 · CA · contact PI
Molecular chaperones and immune tolerance$373,750
R01 · FY2017 · AI · contact PI
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease$336,375
R01 · FY2017 · DK · contact PI
Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance$222,331
P01 · FY2017 · CA · contact PI
Integration of inflammation and cancer by molecular chaperone$177,723
R01 · FY2017 · CA · contact PI
Core 1: Administration and Biostatistics Core$168,948
P01 · FY2017 · CA · contact PI
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy$1,385,205
P01 · FY2016 · CA · contact PI
Thrombocytes in Cancer Immunity$387,236
R01 · FY2016 · CA · contact PI
Chaperone Mechanisms in Innate Immunity$368,750
R01 · FY2016 · AI · contact PI
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease$336,375
R01 · FY2016 · DK · contact PI
Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance$255,712
P01 · FY2016 · CA · contact PI
Core 1: Administration and Biostatistics Core$174,998
P01 · FY2016 · CA · contact PI
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy$1,337,450
P01 · FY2015 · CA · contact PI
Thrombocytes in Cancer Immunity$387,236
R01 · FY2015 · CA · contact PI
Chaperone Mechanisms in Innate Immunity$368,750
R01 · FY2015 · AI · contact PI
Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance$223,769
P01 · FY2015 · CA · contact PI
Core 1: Administration and Biostatistics Core$169,210
P01 · FY2015 · CA · contact PI
Chaperone Mechanisms in Innate Immunity$368,750
R01 · FY2014 · AI · contact PI
Chaperone Mechanisms in Innate Immunity$346,625
R01 · FY2013 · AI · contact PI
gp96, TLR and immunologic tolerance$339,728
R01 · FY2013 · AI · contact PI
Chaperone Mechanisms in Innate Immunity$368,750
R01 · FY2012 · AI · contact PI
gp96, TLR and immunologic tolerance$361,412
R01 · FY2012 · AI · contact PI
Roles and Mechanisms of gp96 in Chaperoning Innate Immunity$409,198
R01 · FY2011 · AI · contact PI
gp96, TLR and immunologic tolerance$361,412
R01 · FY2011 · AI · contact PI
Novel Chaperone Mechanism for Platelet Disorder$500,000
RC1 · FY2010 · HL · contact PI
Roles and Mechanisms of gp96 in Chaperoning Innate Immunity$409,115
R01 · FY2010 · AI · contact PI
gp96, TLR and immunologic tolerance$365,063
R01 · FY2010 · AI · contact PI
Novel Chaperone Mechanism for Platelet Disorder$500,000
RC1 · FY2009 · HL · contact PI
gp96, TLR and immunologic tolerance$380,001
R01 · FY2009 · AI · contact PI
Roles and Mechanisms of gp96 in Chaperoning Innate Immunity$362,970
R01 · FY2009 · AI · contact PI
Roles and Mechanisms of gp96 in Chaperoning Innate Immunity$37,332
R01 · FY2009 · AI · contact PI
Roles and Mechanisms of gp96 in Chaperoning Innate Immunity$362,970
R01 · FY2008 · AI · contact PI
Roles and Mechanisms of gp96 in Chaperoning Innate Immunity$370,000
R01 · FY2007 · AI · contact PI
Role of cell surface HSP gp96 in immunity$225,478
R01 · FY2007 · CA · contact PI
Role of cell surface HSP gp96 in immunity$232,212
R01 · FY2006 · CA · contact PI
Role of cell surface HSP gp96 in immunity$237,800
R01 · FY2005 · CA
Extracellular Targeted Heat Shock Protein Tumor Vaccine$135,610
K08 · FY2005 · CA
HSP VACCINE FOR BREAST CANCER$624
M01 · FY2005 · RR
Role of cell surface HSP gp96 in immunity$237,800
R01 · FY2004 · CA
Extracellular Targeted Heat Shock Protein Tumor Vaccine$135,610
K08 · FY2004 · CA
HSP70 for Treatment of CML in Chronic Phase$38,015
M01 · FY2004 · RR
HSP70 HPV E7 Peptide$4,776
M01 · FY2004 · RR
HSP Vaccine for Breast Cancer$3,439
M01 · FY2004 · RR
CML Phase II$191
M01 · FY2004 · RR
Extracellular Targeted Heat Shock Protein Tumor Vaccine$135,610
K08 · FY2003 · CA
Extracellular Targeted Heat Shock Protein Tumor Vaccine$135,610
K08 · FY2002 · CA
Extracellular Targeted Heat Shock Protein Tumor Vaccine$135,610
K08 · FY2001 · CA